{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:02Z","timestamp":1792783382779,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC Advanced Grant 835227-3"],"award-info":[{"award-number":["ERC Advanced Grant 835227-3"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["3706\/24"],"award-info":[{"award-number":["3706\/24"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","award":["Prof.-18-682"],"award-info":[{"award-number":["Prof.-18-682"]}],"id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Morris Kahn Foundation"},{"name":"National Center for Gene Therapy and Drugs Based on RNA Technology","award":["CN00000041"],"award-info":[{"award-number":["CN00000041"]}]},{"name":"Tel Aviv University","id":[{"id":"https:\/\/ror.org\/04mhzgx49","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Efficient delivery of small interfering RNA (siRNA) remains a materials challenge because it requires nanocarriers that stabilize polyanionic cargo, support cellular interactions, and enable cytosolic delivery. Although poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) are used due to biocompatibility, biodegradability, and regulatory acceptance, siRNA delivery with PLGA requires interfacial engineering to meet these constraints. Here, a modular double-coated PLGA NP platform (dcNPs2.0) is developed and optimized for siRNA complexation, surface functionalization, and scalable manufacturing. The system comprises a PLGA core coated with a polyethyleneimine (PEI) interlayer to mediate siRNA binding, followed by a hyaluronic acid (HA) outer layer, which improves colloidal stability and promotes CD44-mediated uptake. Process optimization, including transition from batch nanoprecipitation to microfluidic fabrication, provides high yield, excellent reproducibility, narrow size distributions, and increased siRNA loading. X-ray photoelectron spectroscopy confirms hierarchical multilayer assembly. The optimized dcNPs2.0 formulation exhibited robust physicochemical stability during storage, in serum-containing media, and following lyophilization with appropriate cryoprotection. Functional evaluation of dcNPs2.0 demonstrated efficient HA-mediated cellular uptake and effective silencing following siRNA delivery in both two-dimensional monolayers and three-dimensional spheroids of MDA-MB-231 cells. Overall, this work establishes a scalable, rationally engineered PLGA nanoplatform that integrates extracellular targeting with intracellular delivery requirements for siRNA therapeutic applications.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Schematic representation of the development and evaluation of double-coated nanoparticles (dcNPs) for siRNA delivery. dcNPs were designed with a poly(lactide-co-glycolic acid) (PLGA) core, polyethyleneimine (PEI), siRNA, and a hyaluronan (HA) outer coating. The formulation process was optimized from conventional nanoprecipitation, which showed batch-to-batch variability, through process refinement to improve concentration conditions, siRNA loading, and reproducibility, and finally translated to a microfluidic platform (dcNPs 2.0), enabling highly monodisperse, reproducible, and scalable NP production. The optimized dcNPs2.0 were then biologically evaluated for CD44-mediated cellular uptake and intracellular siRNA release, leading to gene silencing in 2D and 3D cancer cell models. Created with BioRender.<\/jats:p>","DOI":"10.1007\/s13346-026-02115-8","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:42:02Z","timestamp":1778276522000},"page":"3956-3971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Double-coated PLGA nanoparticles with hierarchical surface architecture for CD44-targeted siRNA delivery"],"prefix":"10.1007","volume":"16","author":[{"given":"Giuseppe","family":"Longobardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pini","family":"Shekhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Satchi-Fainaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Quaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2115_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02463-y","volume":"24","author":"Y Yan","year":"2025","unstructured":"Yan Y, Liu S, Wen J, He Y, Duan C, Nabavi N, et al. Advances in rna-based cancer therapeutics: pre-clinical and clinical implications. Mol Cancer. 2025;24:251.","journal-title":"Mol Cancer"},{"key":"2115_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2020.102239","volume":"29","author":"MA Subhan","year":"2020","unstructured":"Subhan MA, Torchilin VP. Sirna based drug design, quality, delivery and clinical translation. Nanomedicine. 2020;29:102239.","journal-title":"Nanomedicine"},{"key":"2115_CR3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han SP. The current state and future directions of rnai-based therapeutics. Nat Rev Drug Discov. 2019;18:421\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"2115_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.pharmthera.2006.05.006","volume":"112","author":"N Nishiyama","year":"2006","unstructured":"Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther. 2006;112:630\u201348.","journal-title":"Pharmacol Ther"},{"key":"2115_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52\u201379.","journal-title":"Eur J Pharm Biopharm"},{"key":"2115_CR6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jconrel.2011.12.021","volume":"161","author":"E Markovsky","year":"2012","unstructured":"Markovsky E, Baabur-Cohen H, Eldar-Boock A, Omer L, Tiram G, Ferber S, et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release. 2012;161:446\u201360.","journal-title":"J Control Release"},{"key":"2115_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101\u201324.","journal-title":"Nat Rev Drug Discov"},{"key":"2115_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2025.108546","volume":"81","author":"Z Yao","year":"2025","unstructured":"Yao Z, Liu T, Wang J, Fu Y, Zhao J, Wang X, et al. Targeted delivery systems of sirna based on ionizable lipid nanoparticles and cationic polymer vectors. Biotechnol Adv. 2025;81:108546.","journal-title":"Biotechnol Adv"},{"key":"2115_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1990","volume":"16","author":"G-F Longobardi","year":"2024","unstructured":"Longobardi G-F. Polyester nanoparticles delivering chemotherapeutics: learning from the past and looking to the future to enhance their clinical impact in tumor therapy. WIREs Nanomed Nanobiotechnol. 2024;16:e1990.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"2115_CR10","doi-asserted-by":"crossref","unstructured":"\u00a0Chao Deng\u00a0Z, Yanjiao Jiang, Ru Cheng, Fenghua Meng, Zhiyuan. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects, Nano Today, 7 (2012) 467\u2013480.","DOI":"10.1016\/j.nantod.2012.08.005"},{"key":"2115_CR11","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.addr.2012.01.020","volume":"64","author":"E Fleige","year":"2012","unstructured":"Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev. 2012;64:866\u201384.","journal-title":"Adv Drug Deliv Rev"},{"key":"2115_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","volume":"85","author":"K Hadinoto","year":"2013","unstructured":"Hadinoto K, Sundaresan A, Cheow WS. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. Eur J Pharm Biopharm. 2013;85:427\u201343.","journal-title":"Eur J Pharm Biopharm"},{"key":"2115_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2019.12.024","volume":"319","author":"M Zhang","year":"2020","unstructured":"Zhang M, Chen X, Li C, Shen X. Charge-reversal nanocarriers: an emerging paradigm for smart cancer nanomedicine. J Control Release. 2020;319:46\u201362.","journal-title":"J Control Release"},{"key":"2115_CR14","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1021\/bm5003009","volume":"15","author":"Y Zhong","year":"2014","unstructured":"Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules. 2014;15:1955\u201369.","journal-title":"Biomacromolecules"},{"key":"2115_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/jphp.13098","volume":"71","author":"MF Attia","year":"2019","unstructured":"Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71:1185\u201398.","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"2115_CR16","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"12","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;12(9):1410.","journal-title":"Nat Commun."},{"key":"2115_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01260","volume":"9","author":"S Rezvantalab","year":"2018","unstructured":"Rezvantalab S, Drude NI, Moraveji MK, G\u00fcvener N, Koons EK, Shi Y, et al. PLGA-based nanoparticles in cancer treatment. Front Pharmacol. 2018;9:1260.","journal-title":"Front Pharmacol"},{"key":"2115_CR18","doi-asserted-by":"publisher","first-page":"10287","DOI":"10.1073\/pnas.1401337111","volume":"111","author":"A Swami","year":"2014","unstructured":"Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A. 2014;111:10287\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2115_CR19","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1016\/j.biomaterials.2012.06.026","volume":"33","author":"SI Thamake","year":"2012","unstructured":"Thamake SI, Raut SL, Gryczynski Z, Ranjan AP, Vishwanatha JK. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 2012;33:7164\u201373.","journal-title":"Biomaterials"},{"key":"2115_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","volume":"158","author":"K Ramanlal Chaudhari","year":"2012","unstructured":"Ramanlal Chaudhari K, Kumar A, Megraj Khandelwal VK, Ukawala M, Manjappa AS, Mishra AK, et al. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. J Control Release. 2012;158:470\u20138.","journal-title":"J Control Release"},{"key":"2115_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijpharm.2009.10.014","volume":"385","author":"G Luo","year":"2010","unstructured":"Luo G, Yu X, Jin C, Yang F, Fu D, Long J, et al. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm. 2010;385:150\u20136.","journal-title":"Int J Pharm"},{"key":"2115_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113812","volume":"383","author":"R Khoury","year":"2025","unstructured":"Khoury R, Longobardi G, Barnatan TT, Venkert D, Garc\u00eda Alvarado A, Yona A, et al. Radiation-guided nanoparticles enhance the efficacy of PARP inhibitors in primary and metastatic BRCA1-deficient tumors via immunotherapy. J Control Release. 2025;383:113812.","journal-title":"J Control Release"},{"key":"2115_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr4762","volume":"10","author":"S Koshrovski-Michael","year":"2024","unstructured":"Koshrovski-Michael S, Ajamil DR, Dey P, Kleiner R, Tevet S, Epshtein Y, et al. Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin-expressing cancers. Sci Adv. 2024;10:eadr4762.","journal-title":"Sci Adv"},{"key":"2115_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","volume":"14","author":"J Conniot","year":"2019","unstructured":"Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos AI, et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019;14:891\u2013901.","journal-title":"Nat Nanotechnol"},{"key":"2115_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404159","volume":"11","author":"RC Ac\u00farcio","year":"2024","unstructured":"Ac\u00farcio RC, Kleiner R, Vaskovich-Koubi D, Carreira B, Liubomirski Y, Palma C, et al. Intranasal multiepitope PD-L1-siRNA-based nanovaccine: the next-gen COVID-19 immunotherapy. Adv Sci. 2024;11:e2404159.","journal-title":"Adv Sci"},{"key":"2115_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/1078-0432.CCR-15-1155","volume":"22","author":"S Banerjee","year":"2016","unstructured":"Banerjee S, Modi S, McGinn O, Zhao X, Dudeja V, Ramakrishnan S, et al. Impaired synthesis of stromal components in response to Minnelide improves vascular function, drug delivery, and survival in pancreatic cancer. Clin Cancer Res. 2016;22:415\u201325.","journal-title":"Clin Cancer Res"},{"key":"2115_CR27","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1053\/j.gastro.2013.12.035","volume":"146","author":"L Li","year":"2014","unstructured":"Li L, Hao X, Qin J, Tang W, He F, Smith A, et al. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology. 2014;146:1108\u201318.","journal-title":"Gastroenterology"},{"key":"2115_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11:64.","journal-title":"J Hematol Oncol"},{"key":"2115_CR29","doi-asserted-by":"crossref","unstructured":"\u00a0Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Frontiers in Immunol. 2015; 6.","DOI":"10.3389\/fimmu.2015.00201"},{"key":"2115_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.201800049","volume":"2","author":"JM Rios de la Rosa","year":"2018","unstructured":"Rios de la Rosa JM, Tirella A, Tirelli N. Receptor-targeted drug delivery and the (many) problems we know of: the case of CD44 and hyaluronic acid. Adv Biosyst. 2018;2:1800049.","journal-title":"Adv Biosyst"},{"key":"2115_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201901182","volume":"8","author":"JM Rios de la Rosa","year":"2019","unstructured":"Rios de la Rosa JM, Pingrajai P, Pelliccia M, Spadea A, Lallana E, Gennari A, et al. Binding and internalization in receptor-targeted carriers: the complex role of CD44 in the uptake of hyaluronic acid-based nanoparticles (siRNA delivery). Adv Healthc Mater. 2019;8:e1901182.","journal-title":"Adv Healthc Mater"},{"key":"2115_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2014.10.024","volume":"197","author":"X Han","year":"2015","unstructured":"Han X, Li Z, Sun J, Luo C, Li L, Liu Y, et al. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. J Control Release. 2015;197:29\u201340.","journal-title":"J Control Release"},{"key":"2115_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.semcancer.2008.03.017","volume":"18","author":"R Stern","year":"2008","unstructured":"Stern R. Hyaluronidases in cancer biology. Semin Cancer Biol. 2008;18:275\u201380.","journal-title":"Semin Cancer Biol"},{"key":"2115_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-015-0088-2","volume":"13","author":"S Maiolino","year":"2015","unstructured":"Maiolino S, Russo A, Pagliara V, Conte C, Ungaro F, Russo G, et al. Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells. J Nanobiotechnology. 2015;13:29.","journal-title":"J Nanobiotechnology"},{"key":"2115_CR35","doi-asserted-by":"publisher","first-page":"79670","DOI":"10.18632\/oncotarget.13216","volume":"7","author":"A Russo","year":"2016","unstructured":"Russo A, Maiolino S, Pagliara V, Ungaro F, Tatangelo F, Leone A, et al. Enhancement of 5-FU sensitivity by the proapoptotic rpL3 gene in p53 null colon cancer cells through combined polymer nanoparticles. Oncotarget. 2016;7:79670\u201387.","journal-title":"Oncotarget"},{"key":"2115_CR36","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1039\/C4NR06910B","volume":"7","author":"S Maiolino","year":"2015","unstructured":"Maiolino S, Moret F, Conte C, Fraix A, Tirino P, Ungaro F, et al. Hyaluronan-decorated polymer nanoparticles targeting the CD44 receptor for the combined photo\/chemo-therapy of cancer. Nanoscale. 2015;7:5643\u201353.","journal-title":"Nanoscale"},{"key":"2115_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020278","author":"E Gaio","year":"2020","unstructured":"Gaio E, Conte C, Esposito D, Reddi E, Quaglia F, Moret F. CD44 targeting mediated by polymeric nanoparticles and combination of chlorine TPCS(2a)-PDT and docetaxel-chemotherapy for efficient killing of breast differentiated and stem cancer cells in vitro. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12020278.","journal-title":"Cancers (Basel)"},{"key":"2115_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in siRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133\u201347.","journal-title":"Adv Drug Deliv Rev"},{"key":"2115_CR39","doi-asserted-by":"crossref","unstructured":"\u00a0Nazgol C, Dastgerdi K, Dastgerdi NK, Bayraktutan H, Costabile\u00a0G, Atyabi\u00a0F, Dinarvand R, Longobardi G, Alexander and Claudia. Enhancing siRNA cancer therapy: Multifaceted strategies with lipid and polymer-based carrier systems, International Journal of Pharmaceutics, 2024; 663: 124545.","DOI":"10.1016\/j.ijpharm.2024.124545"},{"key":"2115_CR40","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1021\/acs.molpharmaceut.2c00876","volume":"20","author":"P Carotenuto","year":"2023","unstructured":"Carotenuto P, Pecoraro A, Brignola C, Barbato A, Franco B, Longobardi G, et al. Combining \u03b2-carotene with 5-FU via polymeric nanoparticles as a novel therapeutic strategy to overcome uL3-mediated chemoresistance in p53-deleted colorectal cancer cells. Mol Pharm. 2023;20:2326\u201340.","journal-title":"Mol Pharm"},{"issue":"14","key":"2115_CR41","doi-asserted-by":"publisher","first-page":"18497","DOI":"10.1038\/s41598-024-69495-0","volume":"9","author":"AS Racz","year":"2024","unstructured":"Racz AS, Menyhard M. XPS depth profiling of nano-layers by a novel trial-and-error evaluation procedure. Sci Rep. 2024;9(14):18497.","journal-title":"Sci Rep."},{"key":"2115_CR42","doi-asserted-by":"crossref","unstructured":"Easton CD, Kinnear C, McArthur SL, Gengenbach TR. Practical guides for x-ray photoelectron spectroscopy: Analysis of polymers. J. Vac. Sci. Technol. A 1 2020;38:023207.","DOI":"10.1116\/1.5140587"},{"key":"2115_CR43","doi-asserted-by":"crossref","unstructured":"Gallops C, Ziebarth J, Wang Y. A polymer physics perspective on why PEI is an effective nonviral gene delivery vector. Polym Ther Deliv. 2020;1\u201312.","DOI":"10.1021\/bk-2020-1350.ch001"},{"key":"2115_CR44","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1073\/pnas.92.16.7297","volume":"92","author":"O Boussif","year":"1995","unstructured":"Boussif O, Lezoualc\u2019h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 1995;92:7297\u2013301.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2115_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","volume":"145","author":"G Sahay","year":"2010","unstructured":"Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control Release. 2010;145:182\u201395.","journal-title":"J Control Release"},{"key":"2115_CR46","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/nat.2022.0004","volume":"32","author":"SF Dowdy","year":"2022","unstructured":"Dowdy SF, Setten RL, Cui XS, Jadhav SG. Delivery of RNA therapeutics: the great endosomal escape! Nucleic Acid Ther. 2022;32:361\u20138.","journal-title":"Nucleic Acid Ther"},{"key":"2115_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202503198","author":"M Green Buzhor","year":"2025","unstructured":"Green Buzhor M, Longobardi G, Kandli O, Krinsky A, Avramoff O, Katyal A, et al. Harnessing next-generation 3D cancer models to elucidate tumor-microbiome crosstalk. Adv Healthc Mater. 2025. https:\/\/doi.org\/10.1002\/adhm.202503198.","journal-title":"Adv Healthc Mater"},{"key":"2115_CR48","doi-asserted-by":"crossref","unstructured":"Pozzi S, Scomparin A, Israeli Dangoor S, Rodriguez Ajamil D, Ofek P, Neufeld L, Krivitsky A, Vaskovich-Koubi D, Kleiner R, Dey P, Koshrovski-Michael S, Reisman N, Satchi-Fainaro R. Meet me halfway: Are in vitro 3D cancer models on the way to replace in vivo models for nanomedicine development?. Adv Drug Deliv Rev. 2021;175:113760.","DOI":"10.1016\/j.addr.2021.04.001"},{"key":"2115_CR49","doi-asserted-by":"crossref","unstructured":"Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release. 2012;164:192-204.","DOI":"10.1016\/j.jconrel.2012.04.045"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02115-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02115-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02115-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:58:03Z","timestamp":1790603883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02115-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2115"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02115-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.-F. is a board director at Teva Pharmaceutical Industries Ltd. and receives unrelated research funding from Merck KGaA. R.S.-F. is a cofounder and officer with an equity interest in Selectin Therapeutics Inc., and in ImmuNovation Tx Ltd. All other authors declare no con\ufb02ict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}